193 related articles for article (PubMed ID: 35159680)
1. Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury.
Zhou Q; Doherty J; Akk A; Springer LE; Fan P; Spasojevic I; Halade GV; Yang H; Pham CTN; Wickline SA; Pan H
Nanomaterials (Basel); 2022 Jan; 12(3):. PubMed ID: 35159680
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury.
Zhou Q; Quirk JD; Hu Y; Yan H; Gaut JP; Pham CTN; Wickline SA; Pan H
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047059
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon.
Wu P; Zhou Q; Zhu H; Zhuang Y; Bao J
BMC Cancer; 2020 Apr; 20(1):354. PubMed ID: 32345258
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin Is Not Protective against Ischemic and Cisplatin-Induced Kidney Injury.
Andrianova NV; Zorova LD; Babenko VA; Pevzner IB; Popkov VA; Silachev DN; Plotnikov EY; Zorov DB
Biochemistry (Mosc); 2019 Dec; 84(12):1502-1512. PubMed ID: 31870254
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
6. Local Intratracheal Delivery of Perfluorocarbon Nanoparticles to Lung Cancer Demonstrated with Magnetic Resonance Multimodal Imaging.
Wu L; Wen X; Wang X; Wang C; Sun X; Wang K; Zhang H; Williams T; Stacy AJ; Chen J; Schmieder AH; Lanza GM; Shen B
Theranostics; 2018; 8(2):563-574. PubMed ID: 29290827
[TBL] [Abstract][Full Text] [Related]
7. Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy.
Chen J; Pan H; Lanza GM; Wickline SA
Adv Chronic Kidney Dis; 2013 Nov; 20(6):466-78. PubMed ID: 24206599
[TBL] [Abstract][Full Text] [Related]
8.
Daems N; Verlinden B; Van Hoecke K; Cardinaels T; Baatout S; Michiels C; Lucas S; Aerts A
J Biomed Nanotechnol; 2020 Jun; 16(6):985-996. PubMed ID: 33187593
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin-loaded Poly(lactic-co-glycolic) acid nanoparticles: Preparation, characterization, and in vitro toxicity study for potential intra-articular injection.
Pape E; Parent M; Pinzano A; Sapin-Minet A; Henrionnet C; Gillet P; Scala-Bertola J; Gambier N
Int J Pharm; 2021 Nov; 609():121198. PubMed ID: 34662644
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-loaded poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation.
Zhang Z; Xu L; Chen H; Li X
J Pharm Pharmacol; 2014 Apr; 66(4):557-63. PubMed ID: 24635557
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic oxygen delivery by perfluorocarbon-based colloids.
Krafft MP; Riess JG
Adv Colloid Interface Sci; 2021 Aug; 294():102407. PubMed ID: 34120037
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy.
Parhi P; Mohanty C; Sahoo SK
Acta Biomater; 2011 Oct; 7(10):3656-69. PubMed ID: 21704741
[TBL] [Abstract][Full Text] [Related]
13. Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles.
Zhou Z; Zhang B; Wang H; Yuan A; Hu Y; Wu J
Theranostics; 2018; 8(18):4898-4911. PubMed ID: 30429876
[TBL] [Abstract][Full Text] [Related]
14. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
Kumar P; Lakshmi YS; Kondapi AK
HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression.
Kemp Bohan PM; Chick RC; O'Shea AE; Vreeland TJ; Hickerson AT; Cindass JL; Ensley DC; Hale D; Clifton GT; Sohn VY; Thompson IM; Peoples GE; Liss MA
Cancer Prev Res (Phila); 2021 May; 14(5):551-562. PubMed ID: 33514567
[TBL] [Abstract][Full Text] [Related]
16.
Amir N; Green D; Kent J; Xiang Y; Gorelikov I; Seo M; Blacker M; Janzen N; Czorny S; Valliant JF; Matsuura N
Nucl Med Biol; 2017 Nov; 54():27-33. PubMed ID: 28863330
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta 1 (TGF-beta1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs.
Kawamoto K; Pahuja A; Hering BJ; Bansal-Pakala P
Transpl Immunol; 2010 May; 23(1-2):28-33. PubMed ID: 20307666
[TBL] [Abstract][Full Text] [Related]
18. Role of curcumin in the treatment of acute kidney injury: research challenges and opportunities.
Cai Y; Huang C; Zhou M; Xu S; Xie Y; Gao S; Yang Y; Deng Z; Zhang L; Shu J; Yan T; Wan CC
Phytomedicine; 2022 Sep; 104():154306. PubMed ID: 35809376
[TBL] [Abstract][Full Text] [Related]
19. Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
Liu Y; Dai X; Jiang S; Qahar M; Feng C; Guo D; Wang L; Ma S; Huang L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887373
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
